Showing results (791-800 of 1,344) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|September 14, 2006
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphismA K Tiwari, S N Deshpande, B Lerer, et al.
The Pharmacogenomics Journal|May 17, 2006
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment StudyB R Davis, D K Arnett, E Boerwinkle, et al.
The Pharmacogenomics Journal|February 28, 2007
Low frequency of CYP2D6 poor metabolizers among schizophrenia patientsA Llerena, P Dorado, E M Peñas-Lledó, et al.
The Pharmacogenomics Journal|February 28, 2007
Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritisM Drozdzik, T Rudas, A Pawlik, et al.
The Pharmacogenomics Journal|November 23, 2006
Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathyD Badenhorst, G R Norton, K Sliwa, et al.
The Pharmacogenomics Journal|February 15, 2007
Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyureaQ Ma, D F Wyszynski, J J Farrell, et al.
The Pharmacogenomics Journal|October 25, 2006
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populationsA Zhang, Q Xing, S Qin, et al.
The Pharmacogenomics Journal|December 27, 2006
Diuretic-gene interaction and the risk of myocardial infarction and strokeH Schelleman, O H Klungel, J C M Witteman, et al.
The Pharmacogenomics Journal|December 27, 2006
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptomsJ D Robinson, C Y Lam, J A Minnix, et al.
The Pharmacogenomics Journal|April 27, 2005
Distinct proteomic profiles of amphetamine self-administration transitional statesW M Freeman, K Brebner, S G Amara, et al.
Pageof 135